Moderna (NASDAQ:MRNA) has been using AI (artificial intelligence) for some time now to make its lab processes more efficient. From making mRNAs for researchers to working with tech giants like IBM (NYSE:IBM), Moderna has been a leader in using AI in biotech.

But its recent partnership expansion with OpenAI is a big step forward. The goal of the partnership is to not only change how drugs are found, but also to make the whole company run more smoothly.

Moderna’s COVID-19 vaccine has been a huge success, but as the pandemic slows down, the company has had to change its focus. With annual sales of over $18 billion, the company now wants to diversify its product line and launch up to 15 new products in the next five years, such as vaccines for respiratory illnesses like the flu and treatments for other medical conditions.

Moderna’s strategic investment in AI has already started to pay off. The company has seen big improvements in efficiency and cost savings by using AI tools like ChatGPT Enterprise in its operations. For example, AI analytics help with important decisions like choosing the right doses of vaccines for clinical trials. This saves time and makes it more likely that products will be developed successfully.

Moderna’s initial success with AI can be seen in its financial results. In the first quarter, its selling, general, and administrative expenses went down by 10%. As the company keeps using AI, it is expected to become even more efficient and save even more money, which could speed up drug development and make the company more competitive in the market.

While Moderna’s progress in AI is exciting, investors should also look at the bigger picture, such as how strong its pipeline is and how much revenue it is likely to make in the future. Moderna’s stock price has gone up by about 40% this year, which shows that it is moving in the right direction. With its innovative approach to biotech, Moderna is a good investment for people who want to grow their money over the long term.